Corcept Therapeutics Securities Fraud Class Action
Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.
Corcept Therapeutics · Relacorilant · Ongoing Litigation
Last updated
Case overview
- Defendant company
- Corcept Therapeutics
- Product or service
- Relacorilant
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Lead Plaintiff Application
Participation information
Availability is based on each listed participation option and its deadline.
Lead Plaintiff Application
Investors who purchased or otherwise acquired Corcept shares between October 31, 2024 and December 30, 2025, inclusive, could seek appointment as lead plaintiff.
Eligible investors had to petition the United States District Court for the Northern District of California by April 21, 2026 to serve as lead plaintiff.
- Type
- Law Firm Signup
- Status
- Deadline passed
- Reported proof requirement
- Unclear
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.
- Corcept Therapeutics Securities Fraud Class Action
Barchart.com ·
- Corcept Therapeutics Securities Fraud Class Action
StreetInsider.com ·